Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA ...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...
Welcome to 2024's regulatory tracker for Fierce Pharma. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Pfizer Inc. (NYSE:PFE) is the best gene therapy stock to buy now. Gene therapy ...
Geron's CEO said the company anticipates a peak market potential of $1.2 billion in the US and some key EU countries by 2030. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of ...
Gene therapy is a new medical breakthrough which has, in reality, been several decades in the making. The concept was first suggested 50 years ago as a possibility for targeted treatments, but it ...
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.
NEW YORK, May 31 (UPI) --Researchers are engineering ways to alter genes or swap flawed ones with healthy replacements, hoping to cure diseases or enable the body to better combat them. These ...